EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Anderson Matheus Pereira da Silva, Luciano Falcão Carneiro Filho, Mariana Lee Han, Isabelle Rodrigues Menezes, Elizabeth Honorato de Farias, Marianna Leite, Maria da Vitória Santos do Nascimento, Eryvelton de Souza Franco, Maria Bernadete de Sousa Maia

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.05.004 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Anderson Matheus Pereira da Silva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, PE, Brazil. Electronic address: anderson.mhps@icloud.com. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Consolidation Chemotherapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge, particularly in children, adolescents, and young adults. Blinatumomab, a bispecific T-cell engager targeting CD19-positive leukemic cells, has emerged as an alternative to conventional chemotherapy in post-induction consolidation. This meta-analysis aimed to evaluate its impact on survival outcomes, relapse rates, and treatment-related toxicities. METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing blinatumomab to chemotherapy as post-induction consolidation therapy in children, adolescents, and young adults with first relapse of standard-risk B-ALL were included. Primary outcomes were disease-free survival (DFS) and overall survival (OS). Secondary outcomes included cumulative incidence of relapse, measurable residual disease (MRD) negativity, hematopoietic stem cell transplantation (HSCT) eligibility, and treatment-related toxicities. Effect sizes were estimated using hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI). RESULTS: Four RCTs including 703 patients were analyzed. Blinatumomab was associated with improved disease-free survival (DFS) (HR 0.59; 95% CI, 0.42-0.81) and OS (HR 0.57; 95% CI, 0.43-0.76), as well as a lower cumulative incidence of relapse (HR 0.26; 95% CI, 0.16-0.41). Referral for HSCT was more frequent in the blinatumomab group (RR 1.43; 95% CI, 1.10-1.85). Furthermore, blinatumomab was associated with a higher rate of measurable residual disease (MRD) negativity at the end of the first consolidation cycle (RR 1.96; 95% CI, 1.40-2.76). CONCLUSION: Blinatumomab improved survival outcomes and increased the proportion of patients referred for HSCT, supporting its role as post-induction consolidation therapy for relapsed B-ALL in paediatric and young adult populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificConsolidation ChemotherapyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansRandomized Controlled Trials as TopicAdolescentChildRecurrence

Stichwörter der Autor:innen

Disease-free survivalHematopoietic stem cell transplantationImmunotherapymeasurable residual disease

Substanzen

Antibodies, Bispecificblinatumomab

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, PE, Brazil. Electronic address: anderson.mhps@icloud.com.
  • Department of Medicine, Bahiana School of Medicine and Public Health, Salvador, BA, Brazil.
  • Department of Medicine, University of São Paulo, São Paulo, SP, Brazil.
  • Department of Medicine, State University of Rio Grande do Norte, Natal, RS, Brazil.
  • Department of Medicine, Federal University of Roraima, Boa Vista, RR, Brazil.
  • Department of Medicine, Santa Marcelina College, São Paulo, SP, Brazil.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

da Silva, A. M. P., Filho, L. F. C., Han, M. L., Menezes, I. R., de Farias, E. H., Leite, M., Santos do Nascimento, M. D. V., Franco, E. S., & Maia, M. B. S. (2025). Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.05.004

Vancouver

da Silva AMP, Filho LFC, Han ML, Menezes IR, de Farias EH, Leite M, et al. Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.05.004

BibTeX
@article{daSilva2025,
  author = {da Silva, Anderson Matheus Pereira and Filho, Luciano Falcão Carneiro and Han, Mariana Lee and Menezes, Isabelle Rodrigues and de Farias, Elizabeth Honorato and Leite, Marianna and Santos do Nascimento, Maria da Vitória and Franco, Eryvelton de Souza and Maia, Maria Bernadete de Sousa},
  title = {Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.05.004}
}
Kostenlos starten →